FUJIFILM Holdings Corporation (FUJIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FUJIFILM Holdings Corporation (FUJIF) trades at $20.00 with AI Score 48/100 (Grade C). FUJIFILM Holdings Corporation, established in 1934, is a diversified global entity operating across Imaging, Healthcare, Materials, and Business Innovation sectors. Market cap: $23.91B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for FUJIF: FUJIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FUJIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FUJIF: the 1 perspectives are evenly split.
How is this calculated? →FUJIFILM Holdings Corporation (FUJIF) Healthcare & Pipeline Overview
FUJIFILM Holdings Corporation, established in 1934, is a diversified global entity operating across Imaging, Healthcare, Materials, and Business Innovation sectors. It leverages its extensive technological expertise to provide medical apparatus, biomedical CDMO services, industrial materials, and document solutions, alongside traditional photographic products, serving a broad international client base.
What Is the Investment Thesis for FUJIF?
FUJIFILM Holdings Corporation presents a compelling investment profile driven by its strategic diversification and strong positioning in high-growth sectors, particularly Healthcare and advanced Materials. With a market capitalization of $23.91B and a P/E ratio of 15.36, the company demonstrates a stable valuation relative to its broad operational scope. Its robust profit margin of 8.2% and gross margin of 40.8% highlight efficient operations and strong pricing power across its diverse product portfolio. The company's strategic shift towards healthcare, encompassing medical devices, CDMO services, and regenerative medicine, positions it to capitalize on global demographic trends and increasing healthcare expenditures. Furthermore, its Materials segment benefits from demand in semiconductor, display, and data storage industries. A dividend yield of 2.06% offers income potential, while a low Beta of 0.37 suggests lower volatility compared to the broader market, appealing to investors seeking stability within a growth-oriented framework.
Based on FMP financials and quantitative analysis
FUJIF Key Highlights
- Market capitalization stands at $23.94 billion, reflecting its substantial global presence and diversified business operations.
- The company maintains a P/E ratio of 15.36, indicating a valuation that is competitive within its industrial and healthcare segments.
- A profit margin of 8.2% demonstrates efficient management and profitability across its wide range of products and services.
- Gross margin of 40.8% showcases strong cost control and value retention from its manufacturing and service activities.
- FUJIFILM offers a dividend yield of 2.06%, providing income to shareholders, supported by its consistent operational performance.
Who Are FUJIF's Competitors?
FUJIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRYMF Prysmian S.p.A. | $162.23 | -1.74% | $47.41B | — |
| AMKBF A.P. Møller - Mærsk A/S | $2512.30 | +6.13% | $36.71B | 52 |
| KMTUF Komatsu Ltd. | $41.67 | +8.95% | $37.55B | 49 |
| DTGHF Daimler Truck Holding AG | $47.48 | -0.26% | $36.29B | 39 |
| EJPRF East Japan Railway Company | $18.81 | -10.73% | $21.24B | 46 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FUJIF's Key Strengths?
- Broad diversification across Imaging, Healthcare, Materials, and Business Innovation sectors.
- Strong technological expertise and R&D capabilities, particularly in imaging and materials science.
- Global operational footprint and established market presence.
- Robust financial performance with solid profit and gross margins.
- Strategic shift towards high-growth healthcare and advanced materials segments.
What Are FUJIF's Weaknesses?
- Reliance on traditional imaging products, which may face long-term decline.
- Complexity of managing a highly diversified portfolio across disparate industries.
- Potential for slower growth in mature segments like office devices.
- Exposure to global economic fluctuations affecting industrial and business innovation segments.
What Could Drive FUJIF Stock Higher?
- Strategic expansion of biomedical CDMO services could lead to increased contract wins and revenue growth in the healthcare sector, leveraging global pharmaceutical outsourcing trends.
- Introduction of new medical apparatus or regenerative medicine applications could significantly boost the Healthcare segment's market share and profitability, driven by ongoing R&D.
- Continued global demand for advanced materials in semiconductor and display manufacturing is expected to drive sustained growth in the Materials segment.
- Further penetration of cloud-based solutions and business process outsourcing services within the Business Innovation segment could secure larger enterprise contracts and recurring revenue.
- Development and commercialization of next-generation industrial inkjet technologies could open new revenue streams within the printing and industrial materials markets.
What Are the Key Risks for FUJIF?
- Intense competition across all diversified segments, particularly in the highly regulated healthcare and rapidly evolving technology markets, could pressure margins and market share.
- The 'OTC Other' listing and 'Unknown' disclosure status on the OTC market present significant risks related to liquidity, price transparency, and access to timely financial information for investors.
- Global economic downturns or supply chain disruptions could negatively impact demand for industrial materials, office solutions, and capital expenditure in various industries.
- Rapid technological advancements and shifts in consumer preferences, especially in imaging and business innovation, could render existing products or services obsolete, requiring continuous R&D investment.
- Regulatory changes in the healthcare sector or increased scrutiny of data privacy in business innovation could lead to higher compliance costs or restrict market access.
What Are the Growth Opportunities for FUJIF?
- **Expansion in Biomedical CDMO Services:** The global biomedical contract development and manufacturing organization (CDMO) market is projected for significant growth, driven by increasing pharmaceutical R&D spending and outsourcing trends. FUJIFILM's established expertise in biopharmaceuticals and advanced materials positions it to capture a larger share of this market, which is expected to reach substantial valuations in the coming years. By expanding its CDMO capabilities and capacity, FUJIFILM can secure long-term contracts with pharmaceutical and biotech companies, leveraging its robust manufacturing infrastructure and quality control systems to drive consistent revenue growth over the next 5-10 years.
- **Advancements in Regenerative Medicine:** The field of regenerative medicine, including cell and gene therapies, represents a high-potential growth area within healthcare, with market forecasts indicating rapid expansion. FUJIFILM's involvement in regenerative medicine applications positions it to capitalize on breakthroughs in treating previously incurable diseases. Continued investment in research and development, coupled with strategic partnerships, can enable the company to bring innovative therapies to market. This segment offers the potential for high-margin products and services, contributing significantly to the company's top-line growth over the next decade.
- **Growth in Industrial Materials for Semiconductors and Displays:** The semiconductor and display manufacturing industries are experiencing sustained demand, fueled by the proliferation of 5G technology, AI, and advanced consumer electronics. FUJIFILM's Materials segment provides essential components, such as functional films and materials for image sensors, critical for these high-tech applications. As these industries continue to innovate and scale production, FUJIFILM stands to benefit from increased sales volumes and the development of next-generation materials. This opportunity is ongoing, with market growth tied to global technology adoption cycles.
- **Digital Transformation in Business Innovation:** The Business Innovation segment is poised for growth through the ongoing global digital transformation, particularly in cloud services, workflow solutions, and business process outsourcing (BPO). Companies are increasingly seeking integrated digital solutions to enhance efficiency and reduce operational costs. FUJIFILM's offerings in digital multifunction devices, software, and cloud services cater directly to this demand. By expanding its suite of tailored document services and system integration capabilities, the company can secure larger enterprise contracts and drive recurring revenue streams, with significant market potential over the next 3-7 years.
- **High-Performance Optical Equipment Market:** The demand for high-performance optical equipment, including professional television and cinema lenses, surveillance cameras, and industrial inspection lenses, is expanding. This growth is driven by the increasing sophistication of media production, heightened security needs, and the automation of industrial processes. FUJIFILM's long-standing heritage in optics and precision engineering provides a strong foundation to innovate and capture market share in these specialized segments. Continued product development and market penetration in these niche, high-value areas can contribute to steady revenue growth and maintain the company's premium positioning in optical technology.
What Opportunities Does FUJIF Have?
- Expanding global healthcare market, especially in medical devices, CDMO, and regenerative medicine.
- Increasing demand for advanced materials in semiconductor and display manufacturing.
- Growth in digital transformation and cloud-based solutions for businesses.
- Leveraging existing optical expertise for new applications in surveillance and industrial inspection.
- Strategic acquisitions and partnerships to enhance capabilities in key growth areas.
What Threats Does FUJIF Face?
- Intense competition across all operating segments from specialized and diversified players.
- Rapid technological obsolescence, particularly in digital imaging and IT solutions.
- Regulatory changes and compliance costs, especially in the healthcare sector.
- Supply chain disruptions and raw material price volatility impacting manufacturing costs.
- Economic downturns reducing corporate spending on business innovation and industrial materials.
What Are FUJIF's Competitive Advantages?
- Extensive R&D investment and intellectual property in imaging, materials science, and healthcare technologies.
- Diversified portfolio across multiple high-growth sectors, reducing reliance on any single market.
- Strong global brand recognition and established distribution networks built over decades.
- Proprietary manufacturing processes and specialized chemical expertise in functional films and industrial materials.
- Integrated solutions combining hardware, software, and services, particularly in Business Innovation and Healthcare.
What Does FUJIF Do?
FUJIFILM Holdings Corporation, a global enterprise with its origins tracing back to Tokyo, Japan, in 1934, has evolved from a photographic film manufacturer into a diversified technology conglomerate. The company's operations are strategically segmented into Imaging, Healthcare, Materials, and Business Innovation, serving a vast array of industries and consumers worldwide. Its foundational expertise in imaging science has been a cornerstone for its expansion into new high-growth areas. The Healthcare division represents a significant strategic pivot, offering a comprehensive suite of products and services designed to support prevention, diagnosis, and treatment. This includes advanced medical apparatus, specialized biomedical contract development and manufacturing organization (CDMO) services, pharmaceuticals, and cutting-edge regenerative medicine applications. Beyond clinical applications, FUJIFILM also extends its healthcare offerings to consumer wellness with cosmetics and nutritional supplements, demonstrating a holistic approach to health. In the Materials segment, FUJIFILM leverages its chemical and material science prowess to supply critical components across various industrial applications. This includes inkjet digital presses and printing plates for the printing industry, alongside industrial inkjet-related products and printheads. The company also provides robust storage media and archiving services for managing large digital data volumes, addressing the growing need for secure data preservation. Furthermore, it produces essential industrial materials vital for manufacturing displays, touch panels, semiconductors, image sensors, and functional films, underpinning numerous technology sectors. The Business Innovation segment focuses on enhancing office productivity and graphical communications. It provides a wide range of devices and services for offices, such as digital multifunction devices, printers, software, and cloud-based solutions. This segment also develops workflow solutions tailored for printing enterprises and other organizations within the graphical communications field. Additionally, it delivers customized document services, including system integration and business process outsourcing, to streamline diverse business operations. Finally, the Imaging segment, while representing the company's heritage, continues to innovate. It offers traditional photographic products like color films, instant cameras, photo development and printing systems, and color papers, alongside comprehensive photo printing services. This division also encompasses advanced optical equipment, providing professional television and cinema lenses, high-performance surveillance cameras, specialized industrial lenses for production line inspection, and projectors, showcasing its enduring commitment to optical precision and imaging excellence across professional and industrial domains.
What Products and Services Does FUJIF Offer?
- Develops, manufactures, and markets medical apparatus, pharmaceuticals, and biomedical CDMO services for healthcare.
- Provides industrial materials including inkjet digital presses, printing plates, and materials for semiconductors and displays.
- Offers storage media and archiving services for large digital data volumes.
- Supplies office solutions like digital multifunction devices, printers, software, and cloud services.
- Creates workflow solutions for printing companies and graphical communications sector.
- Delivers tailored document services, system integration, and business process outsourcing.
- Produces traditional photographic products such as color films, instant cameras, and photo printing services.
- Manufactures advanced optical equipment, including TV/cinema lenses, surveillance cameras, and industrial lenses.
How Does FUJIF Make Money?
- Sells medical devices, pharmaceuticals, and provides contract development and manufacturing services in the healthcare sector.
- Generates revenue from the sale of industrial materials, including specialized films, chemicals, and inkjet components to various manufacturing industries.
- Earns income from the sale and servicing of office equipment, software subscriptions, and cloud-based business solutions.
- Provides document services, system integration, and business process outsourcing on a contractual basis.
- Sells photographic products, optical equipment, and offers related printing and development services.
What Industry Does FUJIF Operate In?
FUJIFILM Holdings Corporation operates within a complex and dynamic industry landscape, primarily spanning the Medical - Devices sector within Healthcare, alongside significant contributions to industrial materials and business solutions. In the Medical - Devices industry, the company competes in a market driven by technological advancements, an aging global population, and increasing demand for diagnostic and therapeutic solutions. This sector is characterized by stringent regulatory environments and continuous innovation, where FUJIFILM's expertise in imaging and materials science provides a competitive edge in areas like medical imaging and regenerative medicine. The broader market for industrial materials and business innovation solutions is also highly competitive, influenced by global economic cycles, technological shifts, and the ongoing digital transformation of enterprises. FUJIFILM's diversified portfolio allows it to mitigate risks associated with single-market dependencies and leverage cross-segment synergies, positioning it as a multifaceted player in several critical global industries.
Who Are FUJIF's Key Customers?
- Hospitals, clinics, and healthcare providers globally for medical apparatus and pharmaceuticals.
- Pharmaceutical and biotechnology companies for biomedical CDMO services.
- Printing industries and graphical communications companies for digital presses and workflow solutions.
- Manufacturers in the display, semiconductor, and image sensor industries for specialized materials.
- Corporate offices and large enterprises for business innovation devices, software, and document services.
- Professional photographers, filmmakers, and industrial clients for optical equipment.
- General consumers for instant cameras, color films, and photo printing services.
Company Profile
FUJIFILM Holdings Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Teiichi Goto. FUJIF has traded publicly since 2006.
How FUJIFILM Holdings Corporation Is Valued
FUJIFILM Holdings Corporation carries a market capitalization of $23.91B, placing it in the large-cap category. Relative to its peer group, FUJIF's quantitative score of 48/100 is roughly in line with the peer average of 47/100.
ROE 8%Key Financial Metrics
Return on equity for FUJIFILM Holdings Corporation stands at 7.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.6%, showing how much profit it generates from its asset base. FUJIF trades at a trailing price-to-earnings ratio of 14.71, below the Healthcare sector average of ~23x. Its free cash flow yield is -2.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
FUJIFILM Holdings Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.65 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project FUJIFILM Holdings Corporation revenue of about $3.33T for fiscal 2026, with EPS near $222.99. The estimate reflects 14 contributing analysts.
FUJIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the growth potential.
- Community sentiment has shifted positively, with discussions highlighting FUJIFILM's innovative advancements in healthcare and imaging technology.
- Analysts are increasingly recognizing FUJIFILM's diversification strategy, particularly in biotechnology, as a solid growth driver.
- The company's strong brand reputation in imaging and printing continues to resonate well with consumers, enhancing market perception.
Bear Case
- Concerns over supply chain disruptions have emerged, potentially impacting production timelines and operational efficiency.
- Some community members express skepticism about FUJIFILM's ability to maintain growth amid increasing competition in the healthcare sector.
- Market perception is slightly dampened by ongoing regulatory challenges in the pharmaceutical space, raising uncertainty.
- Recent earnings calls have highlighted potential headwinds, causing some investors to question the sustainability of current business strategies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
FUJIF Latest News
No recent news available for FUJIF.
FUJIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FUJIF.
Price Targets
Wall Street price target analysis for FUJIF.
FUJIF MoonshotScore
What does this score mean?
The MoonshotScore rates FUJIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Teiichi Goto
Unknown
Details regarding specific career history, education, and previous roles for Teiichi Goto are not provided in the source data. He is noted as managing 72,254 employees globally for FUJIFILM Holdings Corporation.
Track Record: Specific achievements, strategic decisions, and company milestones under Teiichi Goto's leadership are not detailed in the provided source material.
FUJIF OTC Market Information
FUJIFILM Holdings Corporation trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in this tier are typically not required to provide regular financial reports to the SEC or OTC Markets, resulting in significantly less transparency compared to companies listed on major exchanges like NYSE or NASDAQ, which have stringent reporting obligations. Investors considering 'OTC Other' stocks must be aware of the limited information available, which can impact investment decisions and risk assessment.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status means investors have restricted access to financial reports and company updates, making informed decisions difficult.
- Lower Liquidity: Trading on the 'OTC Other' tier often results in lower trading volumes and wider bid-ask spreads, making it challenging to buy or sell shares efficiently.
- Price Volatility: Due to lower liquidity and less information, OTC stocks can be subject to higher price volatility and greater price manipulation risks.
- Regulatory Oversight: OTC markets, especially the 'OTC Other' tier, have less stringent regulatory oversight compared to major exchanges, offering fewer investor protections.
- Difficulty in Valuation: The lack of comprehensive and timely financial data makes it significantly harder for investors to accurately value the company.
- Verify the company's official website for any direct financial reports or investor relations sections.
- Research independent news sources and reputable financial databases for any available company information.
- Assess the company's business model and market position based on available public descriptions.
- Investigate any known legal or regulatory actions against the company.
- Consider the company's global presence and operational scale as indicators of legitimacy.
- Evaluate the company's long-term business strategy and diversification efforts.
- Understand the risks associated with investing in illiquid securities with limited disclosure.
- Established Global Presence: FUJIFILM Holdings Corporation is a well-known global enterprise founded in 1934, indicating a long operational history.
- Significant Employee Base: The company employs 72,254 individuals, suggesting a substantial and active business operation.
- Diversified Business Segments: Operations across Imaging, Healthcare, Materials, and Business Innovation demonstrate a broad and active commercial footprint.
- Headquartered in Tokyo, JP: A major global financial hub, providing a degree of institutional credibility.
- Known CEO: Teiichi Goto is identified as the CEO, indicating clear leadership.
Common Questions About FUJIF (Healthcare)
What are FUJIFILM Holdings Corporation's primary business segments and how do they contribute to its overall strategy?
FUJIFILM Holdings Corporation operates through four primary segments: Imaging, Healthcare, Materials, and Business Innovation. The Imaging segment, while foundational, continues to innovate with optical equipment and traditional photography. Healthcare is a strategic growth driver, encompassing medical devices, CDMO services, pharmaceuticals, and regenerative medicine, aligning with global health trends. The Materials segment provides critical components for industries like semiconductors and printing, leveraging advanced chemical expertise. Business Innovation offers office solutions and workflow services, supporting digital transformation. This diversification allows FUJIFILM to mitigate risks, leverage cross-segment technological synergies, and pursue growth in high-potential markets, particularly healthcare and advanced materials, while maintaining its historical strengths.
What revenue streams does FUJIFILM Holdings Corporation have in healthcare, and what are its key growth opportunities in this sector?
FUJIFILM's Healthcare division generates revenue from a diverse portfolio, including sales of medical apparatus for diagnosis and treatment, biomedical contract development and manufacturing organization (CDMO) services for pharmaceutical companies, and the development and sale of pharmaceuticals and regenerative medicine applications. Additionally, it offers consumer-focused products like cosmetics and nutritional supplements. Key growth opportunities in healthcare include the expansion of its CDMO services to meet increasing demand for outsourced biopharmaceutical manufacturing, advancements in regenerative medicine to address unmet medical needs, and the continuous innovation of medical imaging and diagnostic technologies. These areas are poised for significant market expansion due to global demographic shifts and technological progress.
What are the main risks for FUJIFILM Holdings Corporation, particularly concerning its diversified business model and OTC listing?
FUJIFILM Holdings Corporation faces several risks, compounded by its diversified business model and OTC listing. Operationally, intense competition across its varied segments, from healthcare to industrial materials, could pressure margins. Rapid technological changes in imaging and business innovation necessitate continuous R&D, posing a risk of obsolescence. Economically, global downturns or supply chain disruptions can impact demand for its industrial and business solutions. Critically, its 'OTC Other' listing and 'Unknown' disclosure status on the OTC market present significant investment risks. This tier typically means lower liquidity, wider bid-ask spreads, and limited access to timely financial information, making valuation and trading more challenging and increasing exposure to price volatility and less stringent regulatory oversight.
What are the key factors to evaluate for FUJIF?
FUJIFILM Holdings Corporation (FUJIF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does FUJIF data refresh on this page?
FUJIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FUJIF's recent stock price performance?
FUJIFILM Holdings Corporation (FUJIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Broad diversification across Imaging, Healthcare, Materials, and Business Innovation sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FUJIF overvalued or undervalued right now?
Valuing FUJIFILM Holdings Corporation (FUJIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FUJIF?
Before investing in FUJIFILM Holdings Corporation (FUJIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details were not provided in the source data, so 'Unknown' or 'Not provided' was used while ensuring the object and fields are present as required.
- Specific market sizes and timelines for growth opportunities were inferred from general industry trends as specific numbers were not provided in the source data.
- No analyst ratings or consensus data was provided, so the corresponding FAQ was omitted as per instructions.